JP2012506429A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012506429A5 JP2012506429A5 JP2011533151A JP2011533151A JP2012506429A5 JP 2012506429 A5 JP2012506429 A5 JP 2012506429A5 JP 2011533151 A JP2011533151 A JP 2011533151A JP 2011533151 A JP2011533151 A JP 2011533151A JP 2012506429 A5 JP2012506429 A5 JP 2012506429A5
- Authority
- JP
- Japan
- Prior art keywords
- magnesium
- sequelae
- lipoate
- insulin resistance
- diabetes mellitus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052749 magnesium Inorganic materials 0.000 claims 12
- 239000011777 magnesium Substances 0.000 claims 12
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 11
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 7
- 206010022489 Insulin Resistance Diseases 0.000 claims 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 6
- 241000282412 Homo Species 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000013589 supplement Substances 0.000 claims 3
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical class OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 claims 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims 2
- 230000001447 compensatory effect Effects 0.000 claims 2
- CRGZYKWWYNQGEC-UHFFFAOYSA-N magnesium;methanolate Chemical compound [Mg+2].[O-]C.[O-]C CRGZYKWWYNQGEC-UHFFFAOYSA-N 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000034659 glycolysis Effects 0.000 claims 1
- 235000019136 lipoic acid Nutrition 0.000 claims 1
- -1 magnesium R-(+)-α-lipoic acid salt Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000006371 metabolic abnormality Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229960002663 thioctic acid Drugs 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2008/081128 WO2010047717A1 (en) | 2008-10-24 | 2008-10-24 | Stable, water-insoluble r-(+)-alpha-lipoic acid salt useful for the treatment of diabetes mellitus and its co-morbidities |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012506429A JP2012506429A (ja) | 2012-03-15 |
| JP2012506429A5 true JP2012506429A5 (enExample) | 2012-05-17 |
Family
ID=42119567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011533151A Pending JP2012506429A (ja) | 2008-10-24 | 2008-10-24 | 真性糖尿病及びその共存症の処置に有用である、水に不溶な安定なＲ−（＋）−α−リポ酸塩 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US8222432B2 (enExample) |
| EP (1) | EP2349322A4 (enExample) |
| JP (1) | JP2012506429A (enExample) |
| CA (1) | CA2741700A1 (enExample) |
| WO (1) | WO2010047717A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9999702B2 (en) | 2010-04-09 | 2018-06-19 | Kci Licensing Inc. | Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds |
| US8597264B2 (en) * | 2011-03-24 | 2013-12-03 | Kci Licensing, Inc. | Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds |
| EP3804742A1 (en) | 2013-03-15 | 2021-04-14 | 3M Innovative Properties Company | Wound healing compositions |
| US20200383946A1 (en) * | 2019-05-07 | 2020-12-10 | Aciont Inc. | Lipoic acid formulations |
| CN115536631B (zh) * | 2021-06-30 | 2024-01-30 | 江苏同禾药业有限公司 | 一种高纯度的右旋硫辛酸镁盐的制备方法 |
| CN116041318B (zh) * | 2022-12-29 | 2025-04-18 | 江苏恒沛药物科技有限公司 | 一种制备硫辛酸的方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2115589T3 (es) | 1989-11-09 | 1998-07-01 | Asta Medica Ag | Medicamento que contiene acido r-alfa-liponico o acido s-alfa-liponico como sustancia activa. |
| US5349100A (en) * | 1991-01-02 | 1994-09-20 | Exxon Chemical Patents Inc. | Chiral metallocene compounds and preparation thereof by creation of a chiral center by enantioselective hydride transfer |
| US5545745A (en) * | 1994-05-23 | 1996-08-13 | Sepracor, Inc. | Enantioselective preparation of optically pure albuterol |
| US6288106B1 (en) * | 1999-05-25 | 2001-09-11 | Chronorx, Llc | Processes for the synthesis and use of various α-lipoic acid complexes |
| US6524619B2 (en) * | 2000-01-27 | 2003-02-25 | Chronorx, Inc. | Dosage forms useful for modifying conditions and functions associated with hearing loss and/or tinnitus |
| IT1319195B1 (it) | 2000-10-10 | 2003-09-26 | Laboratorio Chimico Int Spa | Processo per la produzione dell'acido r(+)alfa-lipoico. |
| IT1319196B1 (it) | 2000-10-10 | 2003-09-26 | Laboratorio Chimico Int Spa | Sintesi dell'acido r(+)alfa-lipoico. |
| US6689385B2 (en) * | 2000-11-03 | 2004-02-10 | Chronorx Llc | Formulations for the treatment of insulin resistance and type 2 diabetes mellitus |
| US7030154B2 (en) | 2002-06-07 | 2006-04-18 | Juvenon, Inc. | Stability of lipoic acid |
| CN1896072A (zh) * | 2005-07-16 | 2007-01-17 | 南京莱尔生物化工有限公司 | R－硫辛酸及其盐的制备方法 |
| CN101522658A (zh) * | 2006-06-16 | 2009-09-02 | 因迪基恩药物公司 | 作为抗糖尿病药用于控制糖尿病高血糖症和糖尿病并发症的二甲双胍r-(+)硫辛酸盐 |
| US8324191B2 (en) * | 2008-07-11 | 2012-12-04 | Biolink Life Sciences, Inc | Combined calcium, magnesium and vitamin D supplements |
| US8080674B2 (en) * | 2009-06-12 | 2011-12-20 | Ampac Fine Chemicals Llc. | Preparation of polymer-free R-(+)-α-lipoic acid magnesium salt |
-
2008
- 2008-10-24 EP EP08877632A patent/EP2349322A4/en not_active Withdrawn
- 2008-10-24 JP JP2011533151A patent/JP2012506429A/ja active Pending
- 2008-10-24 US US13/125,724 patent/US8222432B2/en not_active Expired - Fee Related
- 2008-10-24 CA CA2741700A patent/CA2741700A1/en not_active Abandoned
- 2008-10-24 WO PCT/US2008/081128 patent/WO2010047717A1/en not_active Ceased
-
2012
- 2012-07-13 US US13/548,929 patent/US20120283320A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012506429A5 (enExample) | ||
| JP2013525444A5 (enExample) | ||
| SI2498801T1 (en) | A pharmaceutical composition containing desPro36Exendin-4 (1-39) -Lys6-NH2 and methionine | |
| JP2008540394A5 (enExample) | ||
| NZ807894A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
| RU2015132860A (ru) | Композиции инсулинов длительного действия | |
| JP2012520343A5 (enExample) | ||
| JP2010514831A5 (enExample) | ||
| JP6401317B2 (ja) | がんを治療するためのシステム、方法、および製剤 | |
| IL314360B2 (en) | Method for the synthesis of thyroid hormone analogs and their polymorphs | |
| JP2015529229A5 (enExample) | ||
| JP2015503593A5 (enExample) | ||
| JP2015143248A5 (enExample) | ||
| JP2010522710A5 (enExample) | ||
| JP2018530592A5 (enExample) | ||
| MY174002A (en) | Combination theraphy for the treatment of diabetes | |
| ES2982123T3 (es) | Agente para la inmunomodulación de apoyo que contiene ácido propiónico y éster de ácido fumárico | |
| JP2012523395A5 (enExample) | ||
| FI3164125T3 (fi) | Menetelmiä ja koostumuksia liikalihavuuden hoitamiseksi, painonnousun ehkäisemiseksi, painonpudotuksen edistämiseksi, laihtumisen edistämiseksi tai diabeteksen hoitamiseksi tai sen kehittymisen ehkäisemiseksi | |
| JP2013541583A5 (enExample) | ||
| JP2010540519A5 (enExample) | ||
| JP2012533559A5 (enExample) | ||
| JP2011046708A5 (enExample) | ||
| JP2007238598A5 (enExample) | ||
| JP2012508256A5 (enExample) |